Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Collaborator:
University of Athens
Information provided by:
Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier:
NCT00306176
First received: March 22, 2006
Last updated: April 3, 2007
Last verified: April 2007

March 22, 2006
April 3, 2007
January 2005
Not Provided
Cardiovascular risk factors alterations
Same as current
Complete list of historical versions of study NCT00306176 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus
Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

The aim of the present study is to investigate the influence of systemic exercise, rosiglitazone administration and combined pharmaceutical and lifestyle intervention on cardiovascular risk factors

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Type II Diabetes Mellitus
Drug: Rosiglitazone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
October 2006
Not Provided

Inclusion Criteria:

  • Type II diabetes mellitus
  • Poor glycemic control

Exclusion Criteria:

  • Heart failure
  • Renal disease
  • Liver disease
  • Cardiovascular event
Both
40 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Greece
 
NCT00306176
1975
Not Provided
Not Provided
Aristotle University Of Thessaloniki
University of Athens
Study Chair: Christos Liapis, PhD,MD University of Athens,Greece
Aristotle University Of Thessaloniki
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP